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Abstract: 
Desmoid-type fibromatosis, also called desmoid tumor, is a locally aggressive 
myofibroblastic neoplasm that usually arises in deep soft tissue with significant potential for 
local recurrence and displays an unpredictable clinical course. 
β-catenin, the genetic key player of desmoid tumors shows nuclear accumulation due to 
mutationas that prevent its degradation leading to activation of Wnt signaling and 
myofibroblastic cell proliferation.  The corresponding hot spot mutations are located in exon 3 
of the CTNNB1 gene or alternatively, in the APC tumor suppressor gene, most often as a 
germline mutation.  
Multifocal desmoid tumors are very rare and clinical characteristics are poorly understood. 
Here we present seven cases of multifocal desmoid in six sporadic and one familial case.  
Four female and three male patients, aged between 7 and 30 years (mean 18.4 years) were 
identified in a cohort of 1392 cases. Tumors were located in (distal) extremities, thorax, 
breast, abdominal wall, shoulder, and neck. Four patients showed a CTNNB1 mutation and 
one an APC germline mutation. In two sporadic cases no CTNNB1 mutation was identified. 
Four patients showed (multiple) recurrences and one patient was lost to follow-up. 
In conclusion, multifocal desmoid tumors is a very rare disease and may occur in sporadic 
cases that are characterized by recurrent CTNNB1 mutations. However, the underlying 
pathogenesis of multifocal desmoid tumors remains poorly understood with often aggressive 
clinical behavior and challenging therapeutical management. 
 
 
 
This research did not receive any specific grant from funding agencies in the public, 
commercial, or not-for-profit sectors. 
 
Short running title: multifocal desmoid 
Key words: desmoid, fibromatosis, soft tissue tumors 
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Introduction 
 
Desmoid-type fibromatosis, or desmoid  tumor, is a locally aggressive, infiltrative growing 
myofibroblastic lesion with unpredictable clinical behavior. It may originate at any part of the 
body with extremities, abdominal wall and mesentery being the most common sites [1]. The 
peak incidence is in the third decade [1]. 
Desmoid tumors arise sporadically in approximately 90% of the cases with the remaining 
10% being familial [1]. Dysregulation of the Wnt signaling pathway is characteristic in both 
settings with β-catenin being the key player. In sporadic cases, the most common activating 
mutations are located in exon 3 of the CTNNB1 gene (chr 3p22.1) coding for β-catenin. 
Alternatively, in the remaining sporadic cases and the familial cases that occur in the context 
of Gardner syndrome (a form of familial adenomatous polyposis), there is a somatic or 
germline inactivating mutation or allelic deletion in the APC tumor suppressor gene (5q22.2) 
[1-4]. Both mechanisms lead to stabilization of β-catenin with cytoplasmatic and subsequently 
nuclear accumulation. Withhin the nucleus, β-catenin acts as a transcription factor regulating 
cell proliferation of myofibroblastic cells [1,5,6]. 
In the recent years, a paradigm shift in terms of treatment modalities has taken place for 
desmoids tumors and the overall management is increasingly complex. It has been shown that 
invasive treatment should be used with caution because of the potential of recurrence, 
irrespective of the margin status [5, 7-9]. In this context, mutational analysis of CTNNB1 can 
give prognostic information, where the hot spot mutation p.Ser45Phe (p.S45F), has been 
proposed as a possible marker for recurrence [10-12].   
Single cases of multifocal desmoid tumors have been described [13-15], but their genetic and 
clinical characteristics are not well understood. We describe herein a series of multifocal 
desmoid tumors and their mutational status to pay attention on these rare cases. 
 
 
Material and Methods 
 
The cases were collected from the authors’ files and the nationwide network and registry of 
histopathology and cytopathology in the Netherlands. Clinical data and follow-up were 
obtained from the patient records. The study was performed in accordance with the Code of 
Conduct of the Federation of Medical Scientific Societies in the Netherlands. 
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In all cases the tissue was fixed in 4% buffered formalin and embedded in paraffin; 2-4 µm 
thick sections were stained with hematoxylin and eosin and immunohistochemically by the 
labelled Streptavidin Biotin technique using a commercially available antibody against β-
catenin (BD Biosciences, clone 14, dilution 1:100). Appropriate positive and negative 
controls were used throughout. 
DNA was isolated from formalin-fixed, paraffin-embedded material (without decalcification) 
by proteinase K digestion and the crude DNA extract was used in a standard PCR. The hot 
spot region for CTNNB1 was amplified using primers: 5’-
ATGGCCATGGAACCAGACAGA-3’ and 5’-GCTACTTGTTCTTGAGTGAAGGACTG-
3’. The region most frequently mutated in APC (NM_000038.5: amino acids 1200-1580) was 
amplified using the following primer pairs: 1) 5’-CAGATATTCCTTCATCACAGAAAC-3’ 
and 5’-GGAGTATCTTCTACACAATAAGTCTG-3’, 2) 5’-
GCCACTTGCAAAGTTTCTTC-3’ and 5’-TCACAGGATCTTCAGCTGACCT-3’, 3) 5’-
TCAGACGACACAGGAAGCAGAT-3’ and 5’-TTTTGGGTGTCTGAGCACCACT-3’, 4) 
5’-AGCCAGGCACAAAGCTGTTGAA-3’ and 5’-TGTCCAGGGCTATCTGGAAGATCA-
3’, 5) 5’-ACCATGCAGTGGAATGGTAAGTGG-3’ and 5’-
TGGAAGAACCTGGACCCTCTGAA-3’, 6) 5’-TGGACCTAAGCAAGCTGCAGTA-3’ and 
5’-CTGCTCTGATTCTGTTTCATTCCCATTGT-3’, 7) 5’-
TCTGAGCCTCGATGAGCCATTT-3’ and 5’-ACGTGATGACTTTGTTGGCATGG-3’. All 
PCR products were analyzed by fluorescent di-deoxysequencing. 
 
 
Results 
 
Out of 1392 cases, seven cases with multifocal desmoid tumors were selected; 
clinicopathological and genetic results are summarized in Table 1. Of the seven patients four 
were female and three were male. Age ranged from 7-30 years (mean 18.4 years). Lesions 
were located in knee and gluteus (1), thigh and lower leg (1), thigh and foot (2), trunk, 
shoulder and neck (1), lower leg and back (1) and both mammae (1). In all cases neoplasms 
were resected. (Multiple) local recurrences were reported in 4 patients. Two patients 
experienced no recurrences so far and one patient was lost to follow-up. One patient was 
additionally treated with systemic (Lucrin, LHRH antagonist, Tamoxifen) and radiation 
therapy and one patient with radiotherapy only. 
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Coronal contrast-enhanced spinecho T1-weighted MR-images with fat saturation of the 
buttock and proximal (Figure 1) and distal (Figure 2) posterior side of the right lower leg in 
Case 1 showed an irregular lesion compatible with desmoid tumor. The extension of the 
lesion is displayed between the white arrows. 
Histologically, all cases showed classical features of desmoid tumor according to the current 
WHO classification of tumors of soft tissue and bone [16]: lesions consisted of long fascicles 
myofibroblastic cells with monomorphous elongated nuclei. There was a variable collagenous 
background with sometimes coarse collagen bundles. Myxoid features were sometimes 
focally present. Small vessels were found parallel to the fascicles of tumor cells. A 
perivascular edema was often seen (Figure 3). 
Immunohistochemically, nuclear expression of beta catenin was detected in all cases (Figure 
4). 
By Sanger sequencing, mutations in CTNNB1 were found in four cases with p.(Thr41Ala) 
being the most frequent (n=3) (Figure 5). One case harbored a p.(Ser45Phe) mutation. Two 
sporadic cases showed no CTNNB1 mutation and one case was known with a germline APC 
mutation. 
In case 1, 5 and 7 two lesions each were tested and yielded the same mutation.  
 
 
Discussion 
 
It has been shown that desmoid-type fibromatosis derives from mesenchymal progenitor cells 
(MPC) harboring a mutation in the CTNNB1 gene with consecutive β-catenin stabilization [6]. 
The nuclear accumulated protein binds to transducing beta-like protein leading to expression 
of several Wnt/APC/β-catenin pathway target genes including proliferation-stimulating 
factors such as S100A4 resulting in growth of myofibroblastic cells [1].  
The capacity of circulation of  mesenchymal progenitor cells including CTNNB1 mutated 
MPCs could explain multifocal development of this tumor type [6]. This is reflected by the 
occurrence of the same mutation in the different lesions tested per patient in our series (n=3). 
However, cases of multifocal desmoid tumors are exceedingly rare and mostly known in 
patients with germline APC mutations and a subsequent second somatic hit [4]. Different 
CTNNB1 mutations in multifocal diseases are also reported hypothesizing that genetic 
alterations can take place in different stages of myofibroblastic progenitor cells [15]. 
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Our small series consist of mainly sporadic multifocal cases and shows that clinical 
management is naturally more difficult than in the common unilocular cases. In terms of age, 
localization and mutational status the herein described cases are similar to solitary cases 
representing young aged patients with lesions mainly in the lower extremities [1].   
The course of desmoid tumors is unpredictable, as spontaneous regression, long-lasting stable 
disease and disease progression can occur. Reliable and validated predictive factors are 
lacking [1]. In several studies it has been shown that mutational status of the hot spots 
influences prognosis with p.Ser45Phe (p.S45F) CTNNB1 mutation being a risk factor for local 
recurrence after curative intended surgery [10-12]. Nevertheless this is not confirmed by 
others [17,18]. 
In terms of mutational status and associated prognosis of multifocal lesions, we cannot draw 
any conclusion since our series is very small and one case is known with an APC germline 
mutation. However, p.Thr41Ala (p.T41A) is the most common genetic event in our series. 
In our cases, recurrences were common (4/7 cases) and surgical intervention limited in some 
cases due to additional mutilation.  
Multimodality treatment including systemic (targeted) therapy could be of special interest 
[9,19] and identification of reliable clinical or genomic biomarkers predicting behavior of 
(multifocal) desmoid tumors is needed to facilitate a more patient tailored approach for 
successful management.   
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Figure legends 
 
Figure 1 
Coronal contrast-enhanced spinecho T1-weighted MR-images with fat saturation of the 
buttock and proximal posterior side of the right lower leg showed an irregular lesion 
compatible with desmoid tumor. The extension of the lesion is displayed between the white 
arrows (Case 1). 
 
Figure 2 
Coronal contrast-enhanced spinecho T1-weighted MR-images with fat saturation of the 
knee/distal posterior side of the right lower leg showed the second desmoids tumor. The 
extension of the neoplasm is displayed by the white arrows (Case 1). 
 
Figure 3 
Classical features of desmoids tumor showing long fascicles of monomorphic elongated 
myofibroblasts were seen in all cases. 
 
Figure 4 
Immunohistochemistry showed nuclear accumulation of β-catenin in all cases. 
 
Figure 5 
By Sanger sequencing, a c.121A>G (p.Thr41Ala) were detected in three cases. 
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Table 1 
Case 
nr.  
Sex 
(m/f) 
Age of first 
presentation 
(y) 
Tumor 
localisations 
Therapy CTNNB1 
Mutation 
status 
Recurrence 
(after n 
months) 
1 m 13 Knee and 
gluteus 
Resection c.121A>G* 
p.Thr41Ala 
No 
2 f 24 Breasts (left + 
right) 
Resection no mutation 
found 
No 
3 m 17 Upper leg and 
hallux 
Resection c.134C>T; 
p.Ser45Phe 
Upper leg 
(10) and 
hallux (63) 
4 f 27 Upper leg and 
lower leg 
Resection c.121A>G 
p.Thr41Ala 
Lost to 
follow-up 
5 m 11 Upper leg and 
hallux  
Resection c.121A>G* 
p.Thr41Ala 
Hallux (36) 
6 f 30 Abdominal 
wall, thorax, 
back, 
shoulder, neck 
Resection, 
Lucrin, LHRH 
antagonist, 
Tamoxifen, RT 
no mutation 
found 
Multiple, in 
all locations 
(6) 
7 f 7 Ankle, back 
and lower leg 
Resection APC 
mutation* 
(Gardner) 
Ankle (7, 18 
and 28), 
back (10) 
       
 
 
M, male; f, female; * mutation in two lesions tested 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Highlights 
Multifocal desmoid tumors are very rare and clinical characteristics are poorly understood. 
They may occur sporadically and show the same CTNNB1 mutations in different lesions, at 
least in our cases. 
The capacity of circulation of  mesenchymal progenitor cells including CTNNB1 mutated 
MPCs could explain multifocal development of this tumor type. 
Multifocal desmoid tumors can behave aggressively. 
The clinical management is challenging. 
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